Susan Tsai

This paper identifies allele-specific resistance mechanisms to daraxonrasib in pancreatic cancer and demonstrates how these guide effective salvage therapies.

The paper develops a classifier, DeCAF, to identify permissive and restraining cancer-associated fibroblast subtypes from bulk RNAseq data and validates its clinical relevance across multiple cancer types.